Destiny Pharma to Join Equity Development Webinar on Positive Phase 2b Top-line Results for XF-73 Nasal Gel
Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001)
No treatment-related adverse events
Brighton, United Kingdom – 29th March 2021 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that the Company’s management team will host a live presentation on Tuesday 30th March at 3:30pm BST with Equity Development.
On Monday 29th March, the Company was pleased to announce positive top-line results from its Phase 2b clinical study testing its XF-73 nasal gel product in patients undergoing surgery at risk of post-surgical infections such as methicillin-resistant Staphylococcus aureus (MRSA) . The primary efficacy endpoint was met and there were no treatment related safety events. Click on the link to the press release here .
The presentation will be hosted by Neil Clark, Chief Executive Officer and Shaun Claydon, Chief Financial Officer. The online presentation is open to all existing and potential shareholders. Questions can be submitted during the presentation to be addressed at the end.
To register for the Equity Development webinar please click here: https://zoom.us/webinar/register/WN_eIPSQ5KaRYqdy6OIzZZD-A
A recording of the presentation will be available after the event on both the Equity Development website and on the Destiny Pharma website.
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned